{"id":34392,"date":"2014-11-27T09:27:21","date_gmt":"2014-11-27T14:27:21","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=34392"},"modified":"2014-11-27T09:27:21","modified_gmt":"2014-11-27T14:27:21","slug":"in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392","title":{"rendered":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 11\/27\/2014 (wallstreetpr) \u2013\u00a0<strong>Avanir Pharmaceuticals Inc (NASDAQ:AVNR)<\/strong> suffered a blow this week when the U.S. Food and Drug Administration declined to approve its migraine drug device. The company had sought marketing approval for the device, which in many ways has good revenue promise. However, even though the FDA rejected the device, analysts believe that all is not lost for Avanir. They are confident that the product will eventually secure approval only that such cannot happen until next year, <a href=\"http:\/\/www.reuters.com\/article\/2014\/11\/26\/us-avanir-fda-migraine-idUSKCN0JA2BS20141126\" target=\"_blank\">according to Reuters<\/a>.<\/p>\n<p style=\"text-align: justify;\">In its rejection, the FDA cited the root-cause of some errors that were observed in the data that Avanir Pharmaceuticals Inc (NASDAQ:AVNR) obtained from the human trial of the device. The trial specifically sought to establish the safety and efficacy of the device.<\/p>\n<p style=\"text-align: justify;\"><strong>Fresh human data<\/strong><\/p>\n<p style=\"text-align: justify;\">The product in question is known as AVP-825, and it is designed for the delivery a prescribed migraine medicine known as sumatriptan powder. The delivery is made through the nose. Following the FDA objection, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) promised to do more to get the product approved. Such efforts would mean obtaining fresh human trial data for the product for submission next year.<\/p>\n<p style=\"text-align: justify;\">Analysts are confident about the fate of the drug delivery device because the regulator did not raise issues with active ingredient of the product, but the device. Nonetheless, according to analysts at Cowen, the delay in the approval of the device means that its launch would be delayed until 2016.<\/p>\n<p style=\"text-align: justify;\"><strong>Huge market opportunity<\/strong><\/p>\n<p style=\"text-align: justify;\">Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is targeting millions of Americans with its AVP-825 product. According to the CDC, more than 37 million Americans have migraines problem. With confidence expressed by analysts and the market opportunity that awaits AVP-825, there are good reasons to believe that investors are in a good company with Avanir Pharmaceuticals Inc (NASDAQ:AVNR).<\/p>\n<p style=\"text-align: justify;\"><strong>Acquisition target <\/strong><\/p>\n<p style=\"text-align: justify;\">According to Bloomberg, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) could be targeted for acquisition by <strong>Shire PLC (ADR) (NASDAQ:SHPG)<\/strong>. The report also cited <strong>Eli Lilly &amp; Co. (NYSE:LLY)<\/strong> among position acquirers. The reason is that Avanir enjoys some interesting marketing exclusivity. Also, <a href=\"http:\/\/www.bloomberg.com\/news\/2014-10-29\/avanir-inroads-in-alzheimer-s-justify-offers-real-m-a.html\" target=\"_blank\">according to Bloomberg<\/a>, the company\u2019s rich product pipeline could trigger acquisition moves.<\/p>\n<p style=\"text-align: justify;\"><strong>Technicals<\/strong><br \/>\n<a href=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/11\/avnr.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-34398 aligncenter\" src=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/11\/avnr.png\" alt=\"avnr\" width=\"744\" height=\"438\" srcset=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/11\/avnr.png 744w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/11\/avnr-300x177.png 300w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/11\/avnr-93x55.png 93w\" sizes=\"(max-width: 744px) 100vw, 744px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Avanir Pharmaceuticals Inc (NASDAQ:AVNR) has been in a strong uptrend on subdued volumes. The stock is trading above its 20-Day EMA of $13.48 with RSI in overbought zone at 79.14. Going forward the stock has support near $14.7 and $14.30 in near term.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 11\/27\/2014 (wallstreetpr) \u2013\u00a0Avanir Pharmaceuticals Inc (NASDAQ:AVNR) suffered a blow this week when the U.S. Food and Drug Administration declined to approve its migraine [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":32293,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[260,2236,261,264,4],"tags":[2502,1768,2503,6186,1769,6185],"stock_ticker":[],"class_list":["post-34392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-advancers","category-business","category-decliners","category-health","category-nasdaq-high-profiles","tag-avanir-pharmaceuticals-inc-nasdaqavnr","tag-eli-lilly-co-nyselly","tag-nasdaqavnr","tag-nasdaqshpg","tag-nyselly","tag-shire-plc-adr-nasdaqshpg","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 11\/27\/2014 (wallstreetpr) \u2013\u00a0Avanir Pharmaceuticals Inc (NASDAQ:AVNR) suffered a blow this week when the U.S. Food and Drug Administration declined to approve its migraine [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-11-27T14:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View\",\"datePublished\":\"2014-11-27T14:27:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"keywords\":[\"Avanir Pharmaceuticals Inc. (NASDAQ:AVNR)\",\"Eli Lilly &amp; Co (NYSE:LLY)\",\"NASDAQ:AVNR\",\"NASDAQ:SHPG\",\"NYSE:LLY\",\"Shire PLC (ADR) (NASDAQ:SHPG)\"],\"articleSection\":[\"Advancers\",\"Business\",\"Decliners\",\"Health\",\"NASDAQ high profiles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\",\"name\":\"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"datePublished\":\"2014-11-27T14:27:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392","og_locale":"en_US","og_type":"article","og_title":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR","og_description":"Boston, MA 11\/27\/2014 (wallstreetpr) \u2013\u00a0Avanir Pharmaceuticals Inc (NASDAQ:AVNR) suffered a blow this week when the U.S. Food and Drug Administration declined to approve its migraine [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-11-27T14:27:21+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View","datePublished":"2014-11-27T14:27:21+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","keywords":["Avanir Pharmaceuticals Inc. (NASDAQ:AVNR)","Eli Lilly &amp; Co (NYSE:LLY)","NASDAQ:AVNR","NASDAQ:SHPG","NYSE:LLY","Shire PLC (ADR) (NASDAQ:SHPG)"],"articleSection":["Advancers","Business","Decliners","Health","NASDAQ high profiles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392","url":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392","name":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","datePublished":"2014-11-27T14:27:21+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/in-avanir-pharmaceuticals-inc-nasdaqavnrs-rejected-drug-device-analysts-hold-a-different-view-34392#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"In Avanir Pharmaceuticals Inc (NASDAQ:AVNR)\u2019s Rejected Drug Device, Analysts Hold A Different View"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=34392"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34392\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32293"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=34392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=34392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=34392"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=34392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}